AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33947355
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for oral intake once daily for 10 days
Trial: 34044977
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of HVE and intraoral suction device
Trial: 35322001
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor combined with bevacizumab
Trial: 35322001
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with paclitaxel chemotherapy
Trial: 35322001
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor combined with bevacizumab (dMMR patients)
Trial: 35322001
Drug: PD-1 inhibitor
RxNorm normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor combined with bevacizumab (PMMR patients)
Trial: 35322001
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with paclitaxel chemotherapy (dMMR patients)
Trial: 35322001
Drug: Bevacizumab combined
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab combined with paclitaxel chemotherapy (PMMR patients)
Trial: 32488754
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (100 mg daily for 8 weeks)
Trial: 35525238
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) for quitting smoking and weight gain prevention
Trial: 35525238
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) plus contingency management (CM)
Trial: 34284567
Drug: High-dose pulsed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose pulsed methylprednisolone
Trial: 35460734
Drug: Online intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Online intervention adjunct to treatment-as-usual (TAU)
Trial: 35565823
Drug: Catechin group
RxNorm normalized name: catechin
DrugBank: Cianidanol (DB14086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Catechin group (490 mg catechin, 0.14%, containing 59% epi-type catechin, n = 55)
Trial: 35565823
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (0 mg catechin, n = 54)
Trial: 34284808
Drug: Apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apremilast 30 mg BID (with initial dose titration on days 1–6)
Trial: 35793101
Drug: 10-mg balovaptan
RxNorm normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg balovaptan adult-equivalent dose
Trial: 35793101
Drug: 4-mg balovaptan
RxNorm normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-mg balovaptan adult-equivalent dose
Trial: 34414642
Drug: TXA intradermal-microinjection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA intradermal-microinjection every 2 weeks for 3 months
Trial: 36408238
Drug: Jiaotaiwan (2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jiaotaiwan (2-g JTW granules, b.i.d. for 7 days)
Trial: 36408238
Drug: Placebo (2-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2-g placebo granules, b.i.d. for 7 days)
Trial: 36286633
Drug: UDCA Ursofalk
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA Ursofalk (Germany) at a dose of 10 mg/kg for at least 6 months
Trial: 36286633
Drug: UDCA (another
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA (another manufacturer) at a dose of 10 mg/kg for at least 6 months
Trial: 35771692
Drug: Intervention related
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention related to lifestyle change for prediabetes; specific details on dosage and duration not available.
Trial: 35597718
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patch applied 2–8 hours before puncture.
Trial: 35597718
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (only covering material).
Trial: 32318963
Drug: Low-dose DOACs
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DOACs (edoxaban or rivaroxaban)
Trial: 32318963
Drug: Normal-dose DOACs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-dose DOACs (edoxaban or rivaroxaban)
Trial: 32318963
Drug: Rivaroxaban and
RxNorm normalized name: rivaroxaban and acetylsalicylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban and Warfarin (for hemopericardium)
Trial: 33336698
Drug: DOR/3TC/TDF (Doravirine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DOR/3TC/TDF (Doravirine 100 mg, Lamivudine 300 mg, Tenofovir Disoproxil Fumarate 300 mg)
Trial: 33336698
Drug: EFV/FTC/TDF (Efavirenz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EFV/FTC/TDF (Efavirenz 600 mg, Emtricitabine 200 mg, Tenofovir Disoproxil Fumarate 300 mg)
Trial: 32663852
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g amoxicillin + clavulanic acid 1 hour before surgery and 1 g amoxicillin + clavulanic acid twice a day for 5 days after surgery
Trial: 32663852
Drug: No perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No perioperative antibiotic therapy
Trial: 34378860
Drug: Overall implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall implants
Trial: 35405099
Drug: ACEI/ARB discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ARB discontinuation in mild disease
Trial: 35405099
Drug: ACEI/ARB discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI/ARB discontinuation in moderate disease
Trial: 34333575
Drug: Condoms and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Condoms and the pill
Trial: 32844723
Drug: RUC-4 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUC-4 at 0.05 mg/kg
Trial: 32844723
Drug: RUC-4 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUC-4 at 0.075 mg/kg
Trial: 32844723
Drug: RUC-4 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUC-4 at 0.04 mg/kg
Trial: 34785365
Drug: 10Hz M1‐rTMS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10Hz M1‐rTMS over 2 weeks (real treatment)
Trial: 34785365
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (sham control)
Trial: 32615951
Drug: Crowdsourcing materials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crowdsourcing materials to promote HCV testing (administered once a week for two weeks)
Trial: 33826614
Drug: Alternate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate treatment arm
Trial: 34329577
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin at 1.5 mg/kg on days 1 and 8, combined with ifosfamide (5 g/m2), carboplatin (AUC 5), and etoposide (100 mg/m2) for two 21-day cycles.
Trial: 34329577
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin at 1.5 mg/kg on days 1 and 8, combined with ifosfamide, carboplatin, and etoposide.
Trial: 33000415
Drug: Tongyan Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongyan Spray (通咽喷雾剂) applied to the pharynx 30 min before examination
Trial: 33953542
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg lobeglitazone sulfate
Trial: 33953542
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 25 mg empagliflozin and 0.5 mg lobeglitazone sulfate
Trial: 32988385
Drug: Mirtazapine (MTZ)
RxNorm normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mirtazapine (MTZ) 10 mg/kg for 30 days in HET mice
Trial: 35417538
Drug: BCG +
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG + Oral Polio Vaccine (OPV) immediately
Trial: 35417538
Drug: BCG +
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCG + Oral Polio Vaccine (OPV) at hospital discharge
Trial: 34184474
Drug: Ampasse (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampasse (5 mg/ml, 5 ml intravenously bolus slowly for 15 days)
Trial: 34184474
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% sodium chloride, 5 ml)
Trial: 35596578
Drug: THC +
RxNorm normalized name: Tetrahydrocannabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: THC + CBD (8 mg THC + 10 mg CBD)
Trial: 35596578
Drug: CBD (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD (600 mg, oral)
Trial: 33583165
Drug: Duloxetine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine + Okada Purifying Therapy (Group II)
Trial: 34165151
Drug: CVRS2 design
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CVRS2 design treatment
Trial: 33345876
Drug: Dapagliflozin-Metformin
RxNorm normalized name: dapagliflozin-metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin-Metformin
Trial: 33096362
Drug: Medication Safety
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication Safety Enhancement (MSE) simulation program with integrated technology
Trial: 35660539
Drug: Pharmacogenomic testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenomic testing for relevant antihypertensive medications
Trial: 33020052
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (100 μg or 4,000 units daily)
Trial: 35022783
Drug: suvorexant 10-20
RxNorm normalized name: suvorexant 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suvorexant 10-20 mg nightly for 4 weeks
Trial: 33493011
Drug: Low-Dose Aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Dose Aspirin (LDA) for 5 of 7 days per week
Trial: 33493011
Drug: Postconception initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Postconception initiation of LDA therapy
Trial: 34320428
Drug: 75 J.cm−2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 J.cm−2 LED, 600 μmol.L−1 curcumin
Trial: 34320428
Drug: 600 μmol.L−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 μmol.L−1 curcumin plus 17% EDTA
Trial: 34320428
Drug: 600 μmol.L−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 μmol.L−1 curcumin plus 18% HEBP
Trial: 34320428
Drug: 600 μmol.L−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 μmol.L−1 curcumin plus 75 J.cm−2 LED
Trial: 34320428
Drug: 600 μmol.L−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 μmol.L−1 curcumin plus 17% EDTA and 75 J.cm−2 LED
Trial: 34320428
Drug: 600 μmol.L−1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 μmol.L−1 curcumin plus 18% HEBP and 75 J.cm−2 LED
Trial: 34529859
Drug: LED treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LED treatment (590, 630, and 850 nm with two tested irradiances each)
Trial: 32176657
Drug: Individually Tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually Tailored Internet-Based Cognitive Behavioral Therapy (ICBT) combined with standard medical treatment
Trial: 32176657
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment plus being on waitlist to ICBT (CONTROL)
Trial: 32176657
Drug: Individually Tailored
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually Tailored Internet-Based Cognitive Behavioral Therapy (ICBT)
Trial: 35412032
Drug: Budesonide orodispersible
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide orodispersible tablet (BOT) 1 mg BID for 6 weeks
Trial: 33933921
Drug: Screening, notifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening, notifying the PCP, and providing enhanced depression treatment
Trial: 33589408
Drug: MitraClip plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitraClip plus maximally tolerated guideline‐directed medical therapy (GDMT)
Trial: 35354299
Drug: Rigorous preclinical
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rigorous preclinical assessment with treatment masking, randomization, and blinded assessment.
Trial: 32428843
Drug: Aquatic exercise
RxNorm normalized name: Mentha aquatica leaf extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aquatic exercise twice a week (2x/w)
Trial: 34896280
Drug: Mindfulness-based music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based music therapy intervention (4 sessions over 12 weeks)
Trial: 34090515
Drug: Pediatric integrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric integrative manual therapy (PIMT) plus caregiver education program
Trial: 33907210
Drug: Photobiomodulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation therapy (PBMT) applied with a GaAlAs laser (wavelength=810 nm) at pre-determined points in the masseter muscle (6 J/cm2, 3 regions, 60 s) or TMJ region (6 J/cm2, 5 points, 30 s) for 7 consecutive days.
Trial: 33907210
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 7 consecutive days.
Trial: 33984725
Drug: Postoperative dose-dense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative dose-dense adjuvant chemotherapy with bevacizumab maintenance after neoadjuvant chemotherapy
Trial: 32562573
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg daily low-dose aspirin
Trial: 33686753
Drug: Abemaciclib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib + endocrine therapy (ET) in MONARCH 2
Trial: 33686753
Drug: Abemaciclib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib + endocrine therapy (ET) in MONARCH 3
Trial: 33896276
Drug: Standard-of-care therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care therapy with two nucleoside reverse transcriptase inhibitors + DRV/r (3DR)
Trial: 33418367
Drug: Bio-psycho-social treatment
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-psycho-social treatment programme (6-7 months)
Trial: 34985366
Drug: rPMS (20Hz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rPMS (20Hz and 2400 pulses to triceps brachii and extensor digitorum muscles daily for two weeks in addition to conventional physiotherapy)
Trial: 33285037
Drug: Viltolarsen 40
RxNorm normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Viltolarsen 40 mg/kg/week
Trial: 33285037
Drug: Viltolarsen 80
RxNorm normalized name: Viltolarsen
DrugBank: Viltolarsen (DB15005)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Viltolarsen 80 mg/kg/week
Trial: 33077839
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (ACT) after radical nephroureterectomy (RNU)
Trial: 32212282
Drug: RWE for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RWE for older drugs
Trial: 35018094
Drug: N‐AbA 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N‐AbA 300 mg
Trial: 35018094
Drug: R‐AbA 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R‐AbA 1000 mg
Trial: 32464936
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (DA)
Trial: 35689208
Drug: Remimazolam tosilate
RxNorm normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Remimazolam tosilate (RT) 0.15 mg/kg with supplemental doses of 0.05 mg/kg as needed
Trial: 35689208
Drug: Propofol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1.5 mg/kg with supplemental doses of 0.5 mg/kg
Trial: 34544853
Drug: 20 extra
RxNorm normalized name: ALCOHOL 100 mL in 20 EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 extra hours of self-selected, task-specific motor therapy starting at 2 to 3 months after stroke (subacute group)
Trial: 34544853
Drug: 20 extra
RxNorm normalized name: ALCOHOL 100 mL in 20 EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 extra hours of self-selected, task-specific motor therapy starting at ?30 days after stroke (acute group)
Trial: 34544853
Drug: 20 extra
RxNorm normalized name: ALCOHOL 100 mL in 20 EXTRACORPOREAL CLOTH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 extra hours of self-selected, task-specific motor therapy starting at ?6 months after stroke (chronic group)
Trial: 35108059
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg intravenously; administered once every 2 weeks for 12 months)
Trial: 34649223
Drug: Remdesivir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remdesivir (200 mg on the first day followed by 100 mg daily for the next 9 days intravenously infused over 30‐60 minutes) in addition to standard care
Trial: 36396600
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual daily activities for 8 weeks)
Trial: 36038172
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 bolus (180,000 IU) maintained by daily dose of 2000 IU
Trial: 36038172
Drug: Zinc gluconate
RxNorm normalized name: Zinc Gluconate
DrugBank: Zinc gluconate (DB11248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc gluconate (40 mg daily)
Trial: 35217796
Drug: Psilocybin 15
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin 15 mg
Trial: 35217796
Drug: Psilocybin 30
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin 30 mg
Trial: 35217796
Drug: LSD (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD (both doses)
Trial: 616788766
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy with Jasmine oil
Trial: 616788766
Drug: Aroma therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aroma therapy with Jasmine oil
Trial: 36109691
Drug: Droperidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (1 mg) + Dexamethasone (5 mg)
Trial: 36109691
Drug: Tropisetron (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron (5 mg) + Dexamethasone (5 mg)
Trial: 36109691
Drug: Dexamethasone (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (5 mg) + Saline (5 ml)
Trial: 33069871
Drug: Current treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current treatment only
Trial: 35105186
Drug: LSD (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSD (50 μg)
Trial: 33295851
Drug: Curcumin-galactomannan (CGM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin-galactomannan (CGM) 500 mg twice daily for 30 days
Trial: 35732486
Drug: Multifaceted quality
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multifaceted quality improvement intervention including monthly feedback, interactive education, action toolbox, and bimonthly surveys.
Trial: 33863775
Drug: Neonatal hyperglycaemia
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonatal hyperglycaemia >8 mmol/L
Trial: 33863775
Drug: Neonatal hyperglycaemia
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonatal hyperglycaemia >8 mmol/L for 3 consecutive days
Trial: 34586459
Drug: Levilimab (LVL)
RxNorm normalized name: elapegademase-lvlr
DrugBank: Levilimab (DB16387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levilimab (LVL) 324 mg
Trial: 32066497
Drug: 1 g/8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g/8 h by continuous infusion (CI)